Blend Therapeutics Appoints Mark Iwicki as Chief Executive Officer

  Blend Therapeutics Appoints Mark Iwicki as Chief Executive Officer

   Pharmaceutical industry leader to drive company growth and strategy with
               initial focus on new classes of cancer therapies

Business Wire

WATERTOWN, Mass. -- December 18, 2012

Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes
of medicines to treat debilitating diseases, announced today the appointment
of Mark Iwicki as the company’s President and Chief Executive Officer and a
member of the board of directors. Mr. Iwicki brings to Blend Therapeutics more
than 23 years of experience as a pharmaceutical industry leader managing all
stages of drug development and in multiple therapeutic areas, including his
most recent positions as Chief Executive Officer of Sunovion Pharmaceuticals
and Chief Commercial Officer of Sepracor.

"With oncology as our initial focus and multiple first-in-class anti-cancer
drugs in our pipeline, we are extremely pleased that Mark, who has a long
track record of success in the biopharma industry, has become Blend’s CEO,”
said Omid Farokhzad, MD, founder and director of Blend Therapeutics and
Associate Professor at Harvard Medical School. "Mark has extensive experience
managing high-performance teams and has been instrumental in the success of
drugs including Prilosec®, Diovan®, Zelnorm®, and Lunesta®. The combination of
his business leadership, strategic vision and drug development expertise will
be a great asset as Blend capitalizes on the vast potential of its platform to
develop entirely new classes of drugs to treat patients with cancer and other
important diseases."

"I am very enthusiastic about the opportunity to grow Blend as a
patient-focused, product-driven company with broad potential to advance novel
cancer therapies," said Mark Iwicki, President and Chief Executive Officer of
Blend Therapeutics. "Blend’s drug discovery engine, which uniquely integrates
nanotechnology with novel drug design, has the potential to unlock new classes
of cancer therapeutics that can address unmet needs of patients, either as
proprietary compounds or in collaboration with world-class partners. I’m
excited to lead Blend into its next stage of growth, which includes continuing
to build a first-tier scientific team as well as adding strong clinical
capabilities to the company."

Mr. Iwicki is a pharmaceutical industry leader with a diverse and extensive
background in general management, drug development and commercialization,
including developing and launching products, driving financial performance and
growing businesses in new markets. Prior to joining Blend, Mr. Iwicki was CEO
of Sunovion Pharmaceuticals, where he provided leadership to the successful
launch of Sunovion and its atypical antipsychotic medicine, Latuda®. At
Sepracor, he served as Chief Commercial Officer for the company’s six marketed
products with over $1.2 billion in annual sales. Mr. Iwicki championed
Sepracor’s corporate strategy, delivering significant shareholder value during
his tenure culminating in the company’s $2.6 billion acquisition by Dainippon
Sumitomo Pharmaceuticals in 2009. Prior to joining Sepracor in 2007, he was
the Senior Vice President and head of the $4 billion cardiovascular business
unit at Novartis Pharmaceuticals, and before that held management positions at
Astra Merck and Merck. Mr. Iwicki holds an MBA from Loyola College and a BS in
Marketing from Ball State University.

About Blend Therapeutics

Blend Therapeutics is a biopharmaceutical company discovering new classes of
medicines that have unique modes of action to result in drugs with
differentiated therapeutic properties. Our proprietary technology, assets and
expertise are built around an integrative R&D process that brings together our
new-molecule drug discovery engine and our patented nanoparticle engineering
platform. Using its drug discovery approach, Blend has created a pipeline of
new molecules and is initially focused on developing innovative cancer drugs.
The company was founded by three leaders in the fields of chemistry and
nanomedicine from the Brigham and Women’s Hospital (BWH)–Harvard Medical
School (HMS), and Massachusetts Institute of Technology (MIT): Dr. Omid
Farokhzad of BWH–HMS, and Dr. Robert Langer and Dr. Stephen J. Lippard of MIT.
Blend has attracted top-tier investors including Flagship Ventures,
NanoDimension, and New Enterprise Associates. For more information, visit
www.blendtx.com.

^Prilosec® is a registered trademark of Astra Zeneca. Diovan® and Zelnorm® are
registered trademarks of Novartis. Lunesta® is a registered trademark of
Sunovion. Latuda® is a registered trademark of Dainippon Sumitomo Pharma Co.

Contact:

Media:
The Yates Network
Kathryn Morris, 845-635-9828
kathryn@theyatesnetwork.com
 
Press spacebar to pause and continue. Press esc to stop.